Clinical Trials Logo

Clinical Trial Summary

Neurotoxic phenomena are among the most common and difficult to treat side effects of chemotherapy. The development of chemotherapy induced peripheral neuropathy (CIPN) is a well-recognized adverse reaction in the peripheral nervous system. Side effects of chemotherapy in the central nervous system, however, particularly changes of cognitive function (in non-medical literature referred to as "chemobrain") are diffuse and difficult to attribute to individual cytostatic drugs. The primary purpose of this study is to assess cognitive function in patients with ovarian and breast cancer before and after systemic chemotherapy with paclitaxel with standardized neuropsychological tests and compare the outcome to patients with benign gynecological tumors and breast cancer without chemotherapy treatment, respectively. Secondary parameters include the assessment of olfactory function, total neuropathy score and cytokine profiles.


Clinical Trial Description

Primary outcome parameter: compound score of standardized neuropsychological test Secondary parameters: - olfactory function (Sniffin Sticks) - total neuropathy score (TNS), reduced version (clinical examination, neurography of sural and peroneal nerve) - cytokine profiling from serum samples (ELISA) - quality of life (questionnaire) - depression screening (questionnaire) - symptoms of polyneuropathy (questionnaire) - symptoms of cognitive impairment (everyday memory test questionnaire) Assessment time points: - baseline (after surgical tumor resection and before chemotherapy) - follow up 1 (3 weeks after last chemotherapy cycle or 21 weeks (control patients)) - follow up 2 (optional; 1 year after chemotherapy completion) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02753036
Study type Observational
Source Charite University, Berlin, Germany
Contact
Status Active, not recruiting
Phase
Start date January 1, 2016
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT02488720 - Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT02813434 - Cerebral Amyloid Imaging Using Florbetapir (AV-45) Phase 3
Completed NCT00400790 - Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane N/A
Completed NCT00052091 - Therapy for Depressed Elders With Thought Problems Phase 3
Completed NCT00267163 - Brain Imaging and Mental Disorders of Aging Intervention Phase 4
Completed NCT00021866 - Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy N/A
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Terminated NCT03696082 - A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines N/A
Completed NCT02918539 - Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Active, not recruiting NCT01708837 - Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction Phase 4
Completed NCT01290939 - Bevacizumab and Lomustine for Recurrent GBM Phase 3
Terminated NCT00548327 - The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype Phase 2
Unknown status NCT00256425 - Cognitive Rehabilitation of Glioma Patients Phase 3
Recruiting NCT03926351 - High Dose Omega 3 in People at Risk for Dementia Phase 2
Completed NCT02118571 - Schizophrenia Cognition Scale Development N/A
Completed NCT01481961 - Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease N/A
Completed NCT00788918 - Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) N/A
Completed NCT00564902 - The Zeaxanthin and Visual Function Study N/A
Completed NCT00529581 - A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis Phase 2